Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190331110 | Endometrium | AEH | regulation of mRNA metabolic process | 77/2100 | 288/18723 | 1.69e-13 | 4.40e-11 | 77 |
GO:000989616 | Endometrium | AEH | positive regulation of catabolic process | 104/2100 | 492/18723 | 9.38e-11 | 1.10e-08 | 104 |
GO:003133116 | Endometrium | AEH | positive regulation of cellular catabolic process | 91/2100 | 427/18723 | 9.15e-10 | 8.31e-08 | 91 |
GO:000640210 | Endometrium | AEH | mRNA catabolic process | 59/2100 | 232/18723 | 9.51e-10 | 8.52e-08 | 59 |
GO:000641716 | Endometrium | AEH | regulation of translation | 94/2100 | 468/18723 | 1.14e-08 | 7.62e-07 | 94 |
GO:000640110 | Endometrium | AEH | RNA catabolic process | 63/2100 | 278/18723 | 3.28e-08 | 1.87e-06 | 63 |
GO:006101310 | Endometrium | AEH | regulation of mRNA catabolic process | 39/2100 | 166/18723 | 5.21e-06 | 1.33e-04 | 39 |
GO:004348810 | Endometrium | AEH | regulation of mRNA stability | 37/2100 | 158/18723 | 9.73e-06 | 2.24e-04 | 37 |
GO:19033137 | Endometrium | AEH | positive regulation of mRNA metabolic process | 30/2100 | 118/18723 | 1.21e-05 | 2.68e-04 | 30 |
GO:003465510 | Endometrium | AEH | nucleobase-containing compound catabolic process | 74/2100 | 407/18723 | 1.78e-05 | 3.65e-04 | 74 |
GO:004427010 | Endometrium | AEH | cellular nitrogen compound catabolic process | 80/2100 | 451/18723 | 2.09e-05 | 4.13e-04 | 80 |
GO:00467009 | Endometrium | AEH | heterocycle catabolic process | 79/2100 | 445/18723 | 2.27e-05 | 4.35e-04 | 79 |
GO:004348710 | Endometrium | AEH | regulation of RNA stability | 38/2100 | 170/18723 | 2.30e-05 | 4.38e-04 | 38 |
GO:00194399 | Endometrium | AEH | aromatic compound catabolic process | 80/2100 | 467/18723 | 7.21e-05 | 1.10e-03 | 80 |
GO:19013619 | Endometrium | AEH | organic cyclic compound catabolic process | 83/2100 | 495/18723 | 1.13e-04 | 1.60e-03 | 83 |
GO:00009568 | Endometrium | AEH | nuclear-transcribed mRNA catabolic process | 26/2100 | 112/18723 | 2.25e-04 | 2.75e-03 | 26 |
GO:00002897 | Endometrium | AEH | nuclear-transcribed mRNA poly(A) tail shortening | 10/2100 | 29/18723 | 8.25e-04 | 7.72e-03 | 10 |
GO:00610147 | Endometrium | AEH | positive regulation of mRNA catabolic process | 20/2100 | 87/18723 | 1.30e-03 | 1.11e-02 | 20 |
GO:00611577 | Endometrium | AEH | mRNA destabilization | 19/2100 | 84/18723 | 2.07e-03 | 1.61e-02 | 19 |
GO:00507797 | Endometrium | AEH | RNA destabilization | 19/2100 | 88/18723 | 3.61e-03 | 2.48e-02 | 19 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
CNOT6 | NK | Breast | ADJ | BECN1,AC090152.1,AL137779.1, etc. | 5.00e-02 | |
CNOT6 | M1MAC | Breast | ADJ | BECN1,AC090152.1,AL137779.1, etc. | 2.58e-02 | |
CNOT6 | M2MAC | Breast | DCIS | BECN1,AC090152.1,AL137779.1, etc. | 2.22e-16 | |
CNOT6 | MON | Breast | DCIS | BECN1,AC090152.1,AL137779.1, etc. | 0.00e+00 | |
CNOT6 | MAST | Breast | Healthy | BECN1,AC090152.1,AL137779.1, etc. | 2.62e-02 | |
CNOT6 | GC | Breast | Healthy | BECN1,AC090152.1,AL137779.1, etc. | 0.00e+00 | |
CNOT6 | TFH | Breast | Healthy | BECN1,AC090152.1,AL137779.1, etc. | 7.74e-03 | |
CNOT6 | M2MAC | Breast | Healthy | BECN1,AC090152.1,AL137779.1, etc. | 1.30e-02 | |
CNOT6 | pDC | Breast | Healthy | BECN1,AC090152.1,AL137779.1, etc. | 3.12e-03 | |
CNOT6 | CD8TRM | Breast | IDC | BECN1,AC090152.1,AL137779.1, etc. | 1.15e-03 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CNOT6 | SNV | Missense_Mutation | rs769929322 | c.1003C>T | p.Arg335Trp | p.R335W | Q9ULM6 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
CNOT6 | SNV | Missense_Mutation | novel | c.569C>A | p.Ser190Tyr | p.S190Y | Q9ULM6 | protein_coding | deleterious(0) | possibly_damaging(0.62) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CNOT6 | SNV | Missense_Mutation | novel | c.1249C>T | p.Pro417Ser | p.P417S | Q9ULM6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CNOT6 | SNV | Missense_Mutation | | c.773N>T | p.Gly258Val | p.G258V | Q9ULM6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT6 | SNV | Missense_Mutation | | c.1066N>A | p.Leu356Ile | p.L356I | Q9ULM6 | protein_coding | tolerated(0.68) | benign(0.052) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT6 | SNV | Missense_Mutation | rs774500626 | c.329G>A | p.Arg110Gln | p.R110Q | Q9ULM6 | protein_coding | tolerated(0.08) | probably_damaging(0.988) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CNOT6 | SNV | Missense_Mutation | | c.1244N>A | p.Ser415Tyr | p.S415Y | Q9ULM6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT6 | SNV | Missense_Mutation | novel | c.1398N>G | p.Phe466Leu | p.F466L | Q9ULM6 | protein_coding | tolerated(0.39) | benign(0.387) | TCGA-DI-A1NO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CNOT6 | SNV | Missense_Mutation | novel | c.374N>C | p.Leu125Ser | p.L125S | Q9ULM6 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CNOT6 | SNV | Missense_Mutation | novel | c.1605N>G | p.Phe535Leu | p.F535L | Q9ULM6 | protein_coding | tolerated(1) | benign(0.001) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |